Loading…
Goldline Pharmaceutical (BSE 544759)₹29.74−3.69%Pharmaceuticals
At the end of the Jun 2026 quarter, Goldline Pharmaceutical's shareholders were: promoters 57.25%, FIIs 5.20%, DIIs 7.82%, public 29.73%. 0.00% of promoter shares were pledged. It had 270 shareholders.
As of · Company filings (shareholding pattern)
| Jun 2026 | |
|---|---|
| Promoters | 57.25% |
| FIIs | 5.20% |
| DIIs | 7.82% |
| Public | 29.73% |
| Promoter shares pledged | 0.00% |
| Number of shareholders | 270 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Amol Laxmikant Mujumdar | Promoter | 28.62% | — |
| Swapan Khandelwal | Promoter | 28.62% | — |
| Sumit Bilgaiyan | Public | 7.00% | — |
| Upsurge Opportunities Fund 1 | DII | 3.93% | — |
| Vikasa India Eif I Fund- Share Class P | FII | 3.79% | — |
| Priya Chandrakant Jalgaonkar | Public | 2.32% | — |
| Sgmp Management Consultancy Private Limited | Public | 1.99% | — |
| M/S Nirman Share Brokers Pvt. Ltd. - Pro Account-Prop | Public | 1.43% | — |
| Meena Nayan Patel | Public | 1.05% | — |
Promoters held 57.25% of Goldline Pharmaceutical at the end of the Jun 2026 quarter.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 5.20% and domestic institutions (DIIs) held 7.82%.
No. The Jun 2026 filing shows no pledged promoter shares.
Goldline Pharmaceutical had 270 shareholders at the end of the Jun 2026 quarter.
Sumit Bilgaiyan (Public) held 7.00% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.